Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment

NCT02326857 | Completed

• 2 other identifiers: 99991505515-C-N055
• Study Type: observational
• Target: 1,334
• Locations: 5 countries
• Sites: 9

Brief Summary

Background: \- Researchers want to learn more about breast cancer in Latin American women. They also want to learn how and why women respond differently to standard treatment. Tissue and blood samples from women with breast cancer are needed to study this disease in order to find new ways to prevent, diagnose, and treat it. Objective: \- To learn more about the biology and genetics of breast cancer in Latin American women. Eligibility: \- Latin American women age 18 and older of all ethnic backgrounds who have clinical stage II or III breast cancer. They must still be active and able to self-care. Design:

• Participants are only agreeing to have extra tissue or blood samples collected. They are also letting tissue left over from surgery be used for research. No procedures outside of standard care will be done.
• Participants may have a medical history, physical exam, and blood tests. They may have a pregnancy test. They may have an ultrasound, mammogram, and other scans. They may have an intravenous needle placed in an arm vein.
• Participants may have a core biopsy. For this, a needle is inserted into the breast. A piece of tissue is extracted.
• Participants who have chemotherapy may have blood taken after treatment/before surgery. Tissue may also be collected.
• Participants will complete a questionnaire. It will ask about their social and economic background. It will ask about their family history of cancer. It will also ask about access to diagnosis and treatment of breast cancer.
• Participants may be followed for up to 5 years.

Conditions

Breast Cancer

Keywords

Molecular Profiles of Breast Cancer in Latin American Women; AJCC 7 Clinical Stage II to III; Breast Cancer Observational Study; Prospective Cohort; Epidemiological, Histological, and Clinical Data

Outcome Measures

Primary Outcomes (1)

• Characterize distribution of invasive breast cancer stage II and III molecular profiles

  This project will provide valuable information on the effectiveness of standard chemotherapy in Latin American women.

  2 years post accrual closure

Secondary Outcomes (6)

• Association of molecular profile with tumor histological type, size,lymph node status and surrogate markers

  2 years post accrual closure

• Proportion of participants in each molecular profile who achieve pCR to neoadjuvant chemotherpay

  2 years post accrual closure

• RCB following neoadjuvant chemotherapy

  2 years post accrual closure

• Predictive and prognostic gene expression signatures

  2 years post accrual closure

• Survival-OS, DFS, and TFF

  2 years post accrual closure

Study Arms (1)

Women with breast cancer

Observational study of women with Stage II/III locally advanced breast cancer in Latin America

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The primary objective of the study is to characterize the distribution of invasive breast cancer stage II or III by immunohistochemistry and gene expression profiles in Latin American women. The study has two parts: Part A is a descriptive, observational part to characterize the molecular profile of breast cancer in Latin American women; Part B, the standard neoadjuvant chemotherapy treatment part of the study, seeks to identify any associations between response to neoadjuvant therapy and the molecular profiles. Participants will be followed for a period of 5 years to determine any associations between the molecular profiles and disease evolution following standard treatment.

You may qualify if:

• Women age greater than or equal to 18 years.
• AJCC 7 clinical stage II or III breast cancer. Clarification: Participants with clinical stage II breast cancer who are later classified as histologically-confirmed stage I will remain on study; participants who are later classified as histologically-confirmed stage IV breast cancer will be taken off study.
• Biopsy-accessible breast tumor or participant candidates for primary surgery.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 1.

You may not qualify if:

• Prior history of non-breast malignancy (excluding in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to enrollment in this study.
• Bilateral invasive or in-situ breast cancer.
• Inflammatory breast cancer.
• Clinical or radiological evidence of distant metastases by computed tomography (CT), chest X-ray, abdominal/thoracic ultrasound, bone scan, and/or liver function tests including total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP), within ranges defined in eligibility criteria for Part B of the study.
• Prior hormone therapy, chemotherapy, biologic, targeted therapies, or radiation therapy for this malignancy. Prior bisphosphonate therapy is allowed.
• Pregnant and lactating women: Effects on a developing human fetus of chemotherapeutic agents at the recommended therapeutic dose remain incompletely defined. For this reason and because these agents may be teratogenic, women of child-bearing potential must agree to use adequate contraception (double barrier methods of birth control or abstinence) prior to study entry and for the duration of study treatment phase. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.
• Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapeutic agents, women who are breastfeeding will be excluded. If a participant is of child-bearing potential (women are not considered of childbearing potential if they are at least 2 years postmenopausal and/or surgically sterile), she must have documented negative serum or negative urine pregnancy tests within 14 days of entry to the study (i.e., within 14 days of signing the informed consent document).
• Subjects with psychiatric illness and/or other specific situations that would limit compliance with study requirements and compromise participant follow-up.
• Lack of ability to understand and willingness to sign a written informed consent document.
• Note: Subjects who were enrolled prior to this amendment will be considered eligible even if the HIV/Hep C and pregnancy test were not preformed due to each country standards.
• ELIGIBILITY CRITERIA FOR PART B OF THE STUDY:
• Histologically confirmed new primary adenocarcinoma of the breast AJCC 7 clinical stage II or III. All histological types are included Hormone status: Any tumor ER/PgR status, any HER2/neu status as measured by local hospital pathology laboratory following US LA CRN standard operating procedures (SOPs).
• Normal organ and marrow function as defined below:
• Absolute neutrophil count greater than or equal to 1500/microL
• Platelets greater than or equal to 100,000/microL

Sponsors & Collaborators

• National Cancer Institute (NCI): lead

Study Sites (9)

Instituto Leloir

Buenos Aires, Argentina

Location

Instituto Nacional de Cancer (INCA)

Rio de Janeiro, Brazil

Location

Instituto do C(SqrRoot) ncer do Estado de S(SqrRoot) o Paulo

São Paulo, Brazil

Location

Instituto de Salud Publica

Santiago, Chile

Location

Instituto Jalisciense de Cancerologia

Guadalajara, Mexico

Location

Universidad de Guadalajara

Guadalajara, Mexico

Location

Universidad de Sonora

Sonora, Mexico

Location

Institito Nacional de C(SqrRoot)(Degree)ncer

Montevideo, Uruguay

Location

Instituto Pasteur de Montevideo

Montevideo, Uruguay

Location

Related Publications (4)

• Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52. doi: 10.1038/35021093.

  PMID: 10963602 BACKGROUND

• Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006 Mar 1;24(7):1037-44. doi: 10.1200/JCO.2005.02.6914.

  PMID: 16505422 BACKGROUND

• Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009 Jun;18(6):883-93. doi: 10.1089/jwh.2008.1127.

  PMID: 19514831 BACKGROUND

• Llera AS, Abdelhay ESFW, Artagaveytia N, Daneri-Navarro A, Muller B, Velazquez C, Alcoba EB, Alonso I, Alves da Quinta DB, Binato R, Bravo AI, Camejo N, Carraro DM, Castro M, Castro-Cervantes JM, Cataldi S, Cayota A, Cerda M, Colombo A, Crocamo S, Del Toro-Arreola A, Delgadillo-Cisterna R, Delgado L, Dreyer-Breitenbach M, Fejerman L, Fernandez EA, Fernandez J, Fernandez W, Franco-Topete RA, Gabay C, Gaete F, Garibay-Escobar A, Gomez J, Greif G, Gross TG, Guerrero M, Henderson MK, Lopez-Munoz ME, Lopez-Vazquez A, Maldonado S, Moran-Mendoza AJ, Nagai MA, Oceguera-Villanueva A, Ortiz-Martinez MA, Quintero J, Quintero-Ramos A, Reis RM, Retamales J, Rivera-Claisse E, Rocha D, Rodriguez R, Rosales C, Salas-Gonzalez E, Sanchotena V, Segovia L, Sendoya JM, Silva-Garcia AA, Trinchero A, Valenzuela O, Vedham V, Zagame L; United States-Latin American Cancer Research Network (US-LACRN); Podhajcer OL. The Transcriptomic Portrait of Locally Advanced Breast Cancer and Its Prognostic Value in a Multi-Country Cohort of Latin American Patients. Front Oncol. 2022 Mar 22;12:835626. doi: 10.3389/fonc.2022.835626. eCollection 2022.

  PMID: 35433488 DERIVED

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Thomas G Gross, M.D.

  National Cancer Institute (NCI)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 25, 2014
• First Posted: December 30, 2014
• Study Start: December 23, 2014
• Primary Completion: December 23, 2014
• Study Completion: September 23, 2020
• Last Updated: September 25, 2020

Record last verified: 2020-09

Locations

CL (1); BR (2); AR (1); ME (3); UR (2)